Anti Kpa alloantibody: Development of a rare alloantibody in a non-Hodgkin's lymphoma patient of Indian origin

Anti-S Alloantibody Underlying Pan Agglutinating Autoantibody in a Patient of Systemic Lupus Erythematosus

Prevalence and specificities of red cell alloantibodies in transfusion-dependent beta thalassemia patients in Yazd

Abstract Background Multiple transfusions in thalassemia patients may lead to antibody production against blood group antigens and hemolytic transfusion reaction might occur. In this study, antibody screening test was performed by tube and gel methods to determine the prevalence and specificity of alloantibodies in thalassemia patients. Materials and Methods In this cross-sectional study, overa...

Non-Hodgkin's lymphoma accompanied by autoimmune hemolytic anemia with anti-e autoantibody.

A 43-year-old male with non-Hodgkin's lymphoma accompanied by autoimmune hemolytic anemia (AIHA). His blood group was group B, CcDEe. Alloantibody was absent in his serum, but autoantibody, a combination of IgG and C3d type which showed anti-e specificity, was present. Although transient improvement of AIHA was achieved by treatment with 60 mg/day of prednisolone, subsequent worsening of the an...

Successful Identification of Anti-f Alloantibody in a Non-transfused Male Patient Employing ID-Micro Typing System Gel Cards®

Anti-f alloantibody is produced by exposure to the f (ce) antigen on red blood cells (RBCs), which is a compound antigen of the Rhesus (Rh) blood group, expressed when both c and e antigens are present in the same haplotype (in cis). Although anti-f alloantibody was first discovered in 1953 and it has rarely been detected, the results of its detection were not reported as images in previous stu...

Inhibition of TC-1 cytokine production, effector cytotoxic T lymphocyte development and alloantibody production by 2,3,7,8-tetrachlorodibenzo-p-dioxin.

2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD), a widespread environmental contaminant and prototypic ligand for the aryl hydrocarbon receptor, is a potent immunotoxicant. To understand the underlying mechanisms of TCDD immunotoxicity, we have characterized the time course of changes in CTL, alloantibody, and cytokine responses to the P815 tumor allograft in C57B1/6 mice treated with 0 or 15 microg...